Acquiring Company
Lineage Cell Therapeutics
Acquired Company
NeuroAirmid Therapeutics
CarlsbadManufacturingBiotechnologyTherapeuticsBiotechnologyHealth CareTherapeuticsDescription
Lineage Cell Therapeutics, Inc. has acquired NeuroAirmid Therapeutics, Inc. along with rights to a clinical-stage program for treating Huntington's disease. This acquisition enhances Lineage's capabilities in the field of neural cell therapies.
Quick answer
Lineage Cell Therapeutics is acquiring NeuroAirmid Therapeutics, announced November 12, 2026. Lineage Cell Therapeutics is based in Carlsbad, California, United States.
- How much did Lineage Cell Therapeutics pay for NeuroAirmid Therapeutics?
- The deal value was not disclosed.
- What does Lineage Cell Therapeutics do?
- Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel or 'off-the-shelf,' cell therapies to address unmet medical needs.
- Where are Lineage Cell Therapeutics and NeuroAirmid Therapeutics based?
- Lineage Cell Therapeutics is based in Carlsbad, California, United States.
- Who are the decision-makers at Lineage Cell Therapeutics?
- Fundz holds 4 contacts at Lineage Cell Therapeutics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Nuformix proposes merger with Biovara (November 11, 2026)
- Abeona Therapeutics to Acquire APT-1011 Assets from Ellodi Pharmaceuticals (November 9, 2026)
- Acrivon Therapeutics Acquires Aqilion’s Drug Development Programs (November 6, 2026)
- BioAdaptives, Inc. to acquire Xycota Biosciences LLC to Expand Biotechnology Portfolio (November 4, 2026)
- Western Microsurgical acquires Q Surgical and Proficient Surgical (October 27, 2026)
- Curium US Holdings LLC to Acquire Lantheus Holdings, Inc. (October 21, 2026)
Who to call at Lineage Cell Therapeutics, and when
When Lineage Cell Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Lineage Cell Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Lineage Cell Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Lineage Cell Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Lineage Cell Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired NeuroAirmid Therapeutics?
NeuroAirmid Therapeutics was acquired by Lineage Cell Therapeutics, based in Carlsbad. The deal was reported on November 12, 2026. Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel or 'off-the-shelf,' cell therapies to address unmet medical needs. Lineage Cell Therapeutics is publicly traded (LCTX) and operates in Manufacturing.
When did Lineage Cell Therapeutics acquire NeuroAirmid Therapeutics?
Lineage Cell Therapeutics's acquisition of NeuroAirmid Therapeutics was reported on November 12, 2026. Lineage Cell Therapeutics, Inc. has acquired NeuroAirmid Therapeutics, Inc. along with rights to a clinical-stage program for treating Huntington's disease. This acquisition enhances Lineage's capabilities in the field of neural cell therapies. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does NeuroAirmid Therapeutics do?
NeuroAirmid Therapeutics, Inc. is a biotechnology company engaged in the development of innovative therapies for neurological diseases. The company is focused on utilizing pluripotent stem cell technology to treat conditions such as Huntington’s disease. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.